2010 Leads Physicians 
World of DTC Marketing
MARCH 23, 2022
85% of accelerated approvals from 2010 to 2020 were for oncology indications. Patients trust their doctors, so the accelerated approval process must be modified to increase their trust with physicians and explain to patients precisely what accelerated drug approval means. Of course not.
Evolve Your Success
AUGUST 28, 2024
Dr. Badia’s journey from his immigrant roots to becoming a leading medical practitioner in Miami is truly inspiring. Learn how a childhood experience with his grandmother’s rheumatoid arthritis ignited his passion for hand surgery, leading to his extensive training at N.Y.U. and a transformative fellowship in Pittsburgh.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Infuse Medical
MAY 2, 2024
Another example of VR application in healthcare is: Sapiens TCS App In 2010, Bard Access Systems (a division of C.R. For example, Infuse Medical offers InfuseVR, enabling physicians to upload CT and MRI scans for immersive demonstration in an interactive VR environment.
PM360
NOVEMBER 29, 2022
1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. At the same time, MSLs are being asked to help inform brand strategy with their learnings from talking to leading healthcare professionals. If you apply the right AI engines, you will get increasingly better insights.
Evolve Your Success
OCTOBER 18, 2022
The idea of trying to sell and influence hospitals and physicians using social media was a joke, but the data said otherwise. The main focus has been this mission that I’ve had since 2015, which is I want to change how we sell and market to physicians in this industry. You have to coach your physician. I burn the boats.
Medgadget
MAY 3, 2023
AI-powered tools can also help identify patterns in medical data that can lead to faster diagnoses and better patient outcomes. In a world of wearables, this can help clinicians spot changes in a patient’s condition earlier than would otherwise be possible, leading to quicker interventions that could potentially save lives.
Pharmaceutical Technology
MARCH 24, 2023
Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. Many experts have concerns that only a few Humira biosimilars will have access to the US market, while the rest will not be listed, thereby leading to lower savings than expected.
Expert insights. Personalized for you.
200 
Let's personalize your content